Multiple Myeloma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa The

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Myeloma pipeline constitutes 100+ key companies continuously working towards developing 130+ Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Multiple Myeloma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple Myeloma Market.

The Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Multiple Myeloma Pipeline Report: https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Multiple Myeloma treatment therapies with a considerable amount of success over the years.
• Multiple Myeloma companies working in the treatment market are Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, and others, are developing therapies for the Multiple Myeloma treatment
• Emerging Multiple Myeloma therapies in the different phases of clinical trials are- P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, and others are expected to have a significant impact on the Multiple Myeloma market in the coming years.
• In February 2023, The marketing authorization application (MAA) for elranatamab was accepted, according to the European Medicines Agency (EMA). The US Food and Drug Administration (FDA) has approved the company's Biologics License Application (BLA) for elranatamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM), according to a separate announcement from Pfizer.
• In December 2022, For the combined development and marketing of the T-cell treatment, CART-ddBCMA, to treat patients with relapsed or refractory multiple myeloma, Kite, a Gilead firm, and Aecellex agreed into a worldwide strategic alliance. The CART-ddBCMA is also undergoing a Phase I clinical trial. As part of the agreement, Arcellx will give Kite an upfront payment of USD 225 million.
• In October 2022, For adult patients with relapsed or refractory multiple myeloma, the FDA granted fast clearance to Janssen Biotech's teclistamab-cqyv, a first bispecific BCMA-directed CD3 T-cell engager.
• In November 2022, Elranatamab received FDA Breakthrough Therapy Designation, according to Pfizer. Elranatamab has also been designated as an orphan drug by the FDA and the EMA for the treatment of MM. Elranatamab has been given Fast Track Designation by the FDA and the PRIME program by the EMA, respectively, for the treatment of patients with RRMM.
• In March 2022, Elranatamab (PF-06863135) against Lenalidomide is the subject of a Phase III investigation by Pfizer that is being conducted in patients with newly diagnosed multiple myeloma who are minimal residual disease positive following autologous stem cell transplantation.
• In February 2021, Elranatamab monotherapy was the subject of an open-label, multicenter, non-randomized Phase II research by Pfizer in patients with multiple myeloma who had failed at least one proteasome inhibitor, one immunomodulatory medication, and one anti-CD38 monoclonal antibody.

Multiple Myeloma Overview
A clonal plasma cell proliferative condition called multiple myeloma (MM) is characterized by an aberrant rise in monoclonal immunoglobulin levels. If left unchecked, the excessive creation of these plasma cells can eventually result in injury to a particular end organ. This is most frequently observed when at least one of the clinical signs of hypercalcemia, renal failure, anemia, or bone pain associated with lytic lesions is present.

Get a Free Sample PDF Report to know more about Multiple Myeloma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:
• P-BCMACD19- ALLO1: Poseida Therapeutics
• ION251: Ionis Pharmaceuticals
• CID-103: CASI Pharmaceuticals
• STI-1492: Sorrento Therapeutics
• Descartes 08: Cartesian Therapeutics
• RAPA-201: Rapa Therapeutics
• PHE885: Novartis
• Venetoclax: AbbVie
• Elranatamab: Pfizer

Multiple Myeloma Route of Administration
Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Multiple Myeloma Molecule Type
Multiple Myeloma Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Multiple Myeloma Pipeline Therapeutics Assessment
• Multiple Myeloma Assessment by Product Type
• Multiple Myeloma By Stage and Product Type
• Multiple Myeloma Assessment by Route of Administration
• Multiple Myeloma By Stage and Route of Administration
• Multiple Myeloma Assessment by Molecule Type
• Multiple Myeloma by Stage and Molecule Type

DelveInsight's Multiple Myeloma Report covers around 130+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Multiple Myeloma product details are provided in the report. Download the Multiple Myeloma pipeline report to learn more about the emerging Multiple Myeloma therapies at:
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Multiple Myeloma Therapeutics Market include:
Key companies developing therapies for Multiple Myeloma are - Karyopharm Therapeutic Inc., Sanofi S.A., Amgen Inc., Takeda Pharmaceutical Company, and Bristol-Myers Squibb Company, and others.

Multiple Myeloma Pipeline Analysis:
The Multiple Myeloma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma Treatment.
• Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Myeloma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Multiple Myeloma drugs and therapies-
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Myeloma Pipeline Market Drivers
• Rising prevalence of multiple myeloma worldwide, increasing investment for healthcare infrastructure are some of the important factors that are fueling the Multiple Myeloma Market.

Multiple Myeloma Pipeline Market Barriers
• However, high costs associated with the treatment of multiple myeloma, lack of healthcare infrastructure in developing economies and other factors are creating obstacles in the Multiple Myeloma Market growth.

Scope of Multiple Myeloma Pipeline Drug Insight
• Coverage: Global
• Key Multiple Myeloma Companies: Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, and others
• Key Multiple Myeloma Therapies: P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, and others
• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
• Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers

Request for Sample PDF Report for Multiple Myeloma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Multiple Myeloma Report Introduction
2. Multiple Myeloma Executive Summary
3. Multiple Myeloma Overview
4. Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment
5. Multiple Myeloma Pipeline Therapeutics
6. Multiple Myeloma Late Stage Products (Phase II/III)
7. Multiple Myeloma Mid Stage Products (Phase II)
8. Multiple Myeloma Early Stage Products (Phase I)
9. Multiple Myeloma Preclinical Stage Products
10. Multiple Myeloma Therapeutics Assessment
11. Multiple Myeloma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Multiple Myeloma Key Companies
14. Multiple Myeloma Key Products
15. Multiple Myeloma Unmet Needs
16 . Multiple Myeloma Market Drivers and Barriers
17. Multiple Myeloma Future Perspectives and Conclusion
18. Multiple Myeloma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Multiple Myeloma Market
https://www.delveinsight.com/report-store/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Multiple Myeloma Epidemiology https://www.delveinsight.com/report-store/multiple-myeloma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Multiple Myeloma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Non-invasive Prenatal Testing Market https://www.delveinsight.com/report-store/non-invasive-prenatal-testing-market
Non-Invasive Prenatal Testing Market By Product Type (Instruments And Kits And Reagents), By Indication (Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, And Others), By End-User (Hospitals, Diagnostic Labs, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chromosomal disorders and the increasing demand for early and non-invasive fetal diagnosis across the globe.

Orthopedic Implants Market https://www.delveinsight.com/report-store/orthopedic-implants-market
Orthopedic Implants Market By Product Type (Hip Implants, Knee Implants, Spinal Implants, Foot And Ankle Implants, And Others), By End-User (Hospitals, Orthopedic Clinics, And Others ), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of orthopedic diseases and rising demand for personalized orthopedic implants.

Analgesics Market
https://www.delveinsight.com/report-store/analgesics-market
Analgesics Market By Product Type (Opioid And Non-Opioid), By Application (Musculoskeletal, Surgical And Trauma, Cancer, And Others), By Drug Type (Prescription And Over-The-Counter (Otc)) By Distribution Channels (Hospital Pharmacy & Retail Pharmacy, And E-Commerce) by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to the increasing prevalence of orthopedic, cancer, and other chronic diseases and rising demand of analgesics for the treatment of mild to moderate pain.

Animal Nutrition Market
https://www.delveinsight.com/report-store/animal-nutrition-market
Animal Nutrition Market By Product Type (Amino Acids, Enzymes, Vitamins And Minerals, Medicated Feed Additives, Antioxidants, And Others), By Animal Type (Poultry, Ruminant, Pet Food, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to rising awareness on animal health and nutrition and increasing industrialisation of livestock production.

Point of Care Diagnostics Market
https://www.delveinsight.com/report-store/point-of-care-diagnostics-market
Point of Care Diagnostics Market By Product Type (Instruments, Kits And Reagents), By Application (Blood Glucose Monitoring, Infectious Diseases, Cardio-Metabolic Diseases, Pregnancy & Fertility Testing, And Others), By End-User (Hospitals, Diagnostic Centers, Home Care Settings, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of infectious and other lifestyle based disorders such as diabetes and cardiovascular diseases and growing awareness on health.

Hyaluronic Acid Viscosupplementation Market
https://www.delveinsight.com/report-store/hyaluronic-acid-viscosupplementation-market
The Hyaluronic Acid Viscosupplementation Market By Treatment Type (Single Injection, Three Injections, And Five Injections), By End-User (Hospitals, Specialty Clinics, And Others), And By Geography Is Expected To Grow At A Steady CAGR forecast till 2028 owing to the increasing prevalence of osteoarthritis, particularly among the geriatric population and increasing demand for non-surgical treatment options for osteoarthritis.

Frozen Food Market
https://www.delveinsight.com/report-store/frozen-food-market
Frozen Foods Market By Product (Fruits & Vegetables, Dairy Products, Meat Products, Seafood Products, And Others), By Product Type (Raw Material, Half-Cooked And Ready-To-Eat), By Distribution Channel (Hypermarkets And Supermarkets, General Stores, E-Commerce, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to rise in the demand for ready-to-eat dishes, overall increase in the average income of individuals, rising work culture in countries, lack of time, usage of foods for extended period and others, along with the rising advancements in delivering quality and preservative-free frozen foods across the globe.

Intrauterine Pressure Catheters Market
https://www.delveinsight.com/report-store/intrauterine-pressure-catheters-market
Intrauterine Pressure Catheters Market By Product (Fluid-Filled Catheters And Transducer Tip Catheters), By End-User (Hospitals, Ambulatory Surgical Centers (ASCS), And Specialty Clinics), and by geography is expected to advance at a respectable CAGR forecast till 2028 owing to the growing number complications in pregnancy and rising focus on maternal and fetal care across the globe.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.